Monthly update of U.S. Food and Drug Administration (FDA) approvals impacting the workers' compensation industry. myMatrixx's report includes new drug and indication approvals, discontinuation and withdrawals, new dosages or formulations of existing products and newly available generics in the last 12 months.
Monthly Drug News
Camber Pharmaceuticals has released diclofenac potassium oral solution, a generic for Depomed’s Cambia®. The non-steroidal anti-inflammatory drug (NSAID) is indicated for treating adults who have acute migraines. Diclofenac potassium solution does not prevent migraines and it is not approved to treat cluster headaches. All NSAIDS have boxed warnings that using them may be associated with cardiovascular (CV) events, such as heart attacks or strokes, and that they may increase the possibility of serious gastrointestinal (GI) side effects, such as bleeding and ulcers.
Impact to Workers’ Comp
Migraine agents may be seen in claims following a head injury. Despite the generic availability, other forms of diclofenac may represent more cost-effective alternatives to its use. For any questions about the use of Cambia, NSAIDs, and potential relatedness to a claim, please consult with your myMatrixx pharmacist.